Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
This strategic decision will unlock significant value for our scientific and industrial products business
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Greg was also central to the planning, design, and construction of this facility
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
Subscribe To Our Newsletter & Stay Updated
